NEW YORK – Jiangsu Alphamab Biopharmaceuticals announced today that it has obtained access to palbociclib (Ibrance) through a supply agreement with Pfizer and that this will enable it to conduct a study combining its investigational KNO26 and palbociclib in HER2-positive breast cancer.